Table 3.

Assigned therapy and treatment discontinuations at follow-up of 24 months

	Cohort 1		Cohort 2		Total
	No.	%	No.	%	No.	%
Imatinib assigned at 24 months, mg	64	61	51	49	115	55
400	9	9	13	12	22	11
600	37	35	32	31	69	33
800	18	17	6	6	24	11
Nilotinib assigned at 24 months	25	24	38	36	63	30
Withdrawn at or before 24 months	16	15	16	15	32	15
AE	3		4		7	3
Progression to AP/BC*	2		3		5	2
Death†			3		3	1
Therapeutic failure‡	4		3		7	3
Other§	7		3		10	5

^*Progression to AP/BC as a primary cause of withdrawal.

^†Death as primary cause of withdrawal.

^‡Failure to achieve milestone responses or loss of response, aside from transformation to AP/BC.

^§The 10 patients in this category discontinued because of protocol violations: failure to comply with therapy (n = 3), withdrawal of consent (n = 3), pregnancy or failure to apply contraception (n = 3), or development of long QTc affecting ability to switch to nilotinib (n = 1).